OVERVIEW

Getting Treatment Right - COVID-19 and Venous Thromboembolism (VTE) is organized by PharmCon, Inc..

Release Date: Monday, November 2, 2020
Offline Date: Sunday, May 2, 2021
ACPE Expiration Date: Sunday, October 29, 2023

Target Audience:
Pharmacists, Nurses

Overview:
Early studies show that patients with COVID-19 appear to be at a higher risk for thrombotic complications like venous thromboembolism (VTE). VTE is already among the leading causes of death from cardiovascular disease. So, in addition to the traditional risk factors for VTE, practitioners must consider both the indirect effects as well as the direct effects of the COVID infection as they contribute to an even greater risk of the consequences of VTE. This program will review the current literature and evidence regarding the frequency of VTE in patients with COVID, as well as the available guidance and evidence-based literature regarding the use of anticoagulation therapies in patients with COVID or patients recovering from COVID.

Learning Objectives:
Pharmacist and Nurse:
• Review the evidence-based literature and current assessment of the need for anticoagulation therapy for prevention of VTE in patients with COVID-19 and/or post COVID-19 patients.
• Choose an anticoagulation treatment plan for VTE in COVID-19 positive patients based on patient specific factors and special considerations to improve patient outcomes.
• Compare and contrast the indications, advantages and potential adverse effects of direct oral anticoagulants for the treatment of VTE.

Nurse
• Review the evidence-based literature and current assessment of the need for anticoagulation therapy for prevention of VTE in patients with COVID-19 and/or post COVID-19 patients.
• Compare and contrast the indications, advantages and potential adverse effects of direct oral anticoagulants for the treatment of VTE.
• Choose an anticoagulation treatment plan for VTE in COVID-19 positive patients based on patient specific factors and special considerations to improve patient outcomes.